Degradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells

Carcinogenesis

Volumn 34, Issue 5, 2013, Pages 990-1000

  Paranjpe, Ameya ^a   Srivenugopal, Kalkunte S ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ALDEHYDE DEHYDROGENASE; BORTEZOMIB; COPPER; DISULFIRAM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; THIOL DERIVATIVE; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CHELATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NITROSYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; RETICULOCYTE LYSATE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPIRIN; CELL LINE, TUMOR; DISULFIRAM; DNA-BINDING PROTEINS; HCT116 CELLS; HT29 CELLS; HUMANS; LIVER; MALE; MICE; NF-KAPPA B; OXIDATION-REDUCTION; PROTEASOME ENDOPEPTIDASE COMPLEX; RABBITS; RETICULOCYTES; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-ACTIVATING ENZYMES;

EID: 84877117741     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt032     Document Type: Article

References (55)

1. Dröge,W. (2002) Free radicals in the physiological control of cell function. Physiol. Rev., 82, 47-95.
2. Kern,J.C. et al. (2005) Free radicals and apoptosis: relationships with glutathione, thioredoxin, and the BCL family of proteins. Front. Biosci., 10, 1727-1738.
3. Klatt,P. et al. (2000) Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur. J. Biochem., 267, 4928-4944.
4. Davide Spadaroa,B. et al. (2010) The redox switch: dynamic regulation of protein function by cysteine modifications. Physiol. Plant., 138, 360-371.
5. Niture,S.K. et al. (2005) S-thiolation mimicry: quantitative and kinetic analysis of redox status of protein cysteines by glutathione-affinity chromatography. Arch. Biochem. Biophys., 444, 174-184.
6. Velu,C.S. et al. (2007) Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry, 46, 7765-7780.
7. Douglas,T.H. et al. (2005) Protein S-nitrosylation: purview and parameters. Nat. Rev. Mol. Cell Biol., 6, 150-166.
8. Ghezzi,P. et al. (2005) Thiol-disulfide balance: from the concept of oxidative stress to that of redox regulation. Antioxid. Redox Signal., 7, 964-972.
9. Gallogly,M.M. et al. (2007) Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr. Opin. Pharmacol., 7, 381-391.
10. Martínez-Ruiz,A. et al. (2007) Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: convergences and divergences. Cardiovasc. Res., 75, 220-228.
11. López-Sánchez,L.M. et al. (2010) Pharmacological impairment of s-nitrosoglutathione or thioredoxin reductases augments protein S-nitrosation in human hepatocarcinoma cells. Anticancer Res., 30, 415-421.
12. Reddie,K.G. et al. (2008) Expanding the functional diversity of proteins through cysteine oxidation. Curr. Opin. Chem. Biol., 10, 1016.
13. Ji,Y. et al. (2003) Activation of microsomal glutathione s-transferase by peroxynitrite. Mol. Pharmacol., 63, 136-146.
14. Davies,K.J. (2001) Degradation of oxidized proteins by the 20S proteasome. Biochimie, 83, 301-310.
15. Souza,J.M. et al. (2000) Proteolytic degradation of tyrosine nitrated proteins. Arch. Biochem. Biophys., 380, 360-366.
16. Jørgensen,C.H. et al. (2011) The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol. Clin. Exp. Res., 35, 1749-1758.
17. Mays,D.C. et al. (1998) Inhibition of recombinant human mitochondrial aldehyde dehydrogenase by two intermediate metabolites of disulfiram. Biochem. Pharmacol., 55, 1099-1103.
18. Gresele,P et al. (2006) Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc. Drug Rev., 24, 148-168.
19. Carini,M. et al. (2002) In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. J. Pharm. Biomed. Anal., 29, 1061-1071.
20. Chen,D. et al. (2004) Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J. Med. Chem., 47, 6914-6920.
21. Cobby,J. et al. (1977) The rapid reduction of disulfiram in blood and plasma. J. Pharmacol. Exp. Ther., 202, 724-731.
22. Aslam,M.A. et al. (2010) Cys-141 glutathionylation of human p53: studies using specific polyclonal antibodies in cancer samples and cell lines. Free Radic. Biol. Med., 49, 908-917.
23. Liu,Y. et al. (2001) Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting. Cancer Res., 61, 5402-5406.
24. Rossi,R. et al. (2006) Protein S-glutathionylation and platelet anti-aggregating activity of disulfiram. Biochem. Pharmacol., 72, 608-615.
25. Williams,J.L. et al. (2011) Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: relevance to its mechanism of action. Exp. Cell Res., 317, 1359-1367.
26. Wang,F. et al. (2011) A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells. Cancer Lett., 300, 87-95.
27. Rainwater,R. et al. (1995) Role of cysteine residues in regulation of p53 function. Mol. Cell. Biol., 15, 3892-3903.
28. Maillet,A. et al. (2012) Redox regulation of p53, redox effectors regulated by p53: a subtle balance. Antioxid. Redox Signal., 16, 1285-1294.
29. Yang,S. et al. (2009) Apurinic/apyrimidinic endonuclease/redox effector factor-1(APE/Ref-1): a unique target for the prevention and treatment of human melanoma. Antioxid. Redox Signal., 11, 639-650.
30. Kim,Y.J. et al. (2011) S-glutathionylation of cysteine 99 in the APE1 protein impairs abasic endonuclease activity. J. Mol. Biol., 414, 313-326.
31. Baugh,J.M. et al. (2009) Proteasomes can degrade a significant proportion of cellular proteins independent of ubiquitination. J. Mol. Biol., 386, 814-827.
32. Moreau,P. et al. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood, 120, 947-959.
33. Viquez,O.M. et al. (2012) Electrophilic adduction of ubiquitin activating enzyme E1 by N,N-diethyldithiocarbamate inhibits ubiquitin activation and is accompanied by striatal injury in the rat. Chem. Res. Toxicol., 25, 2310-2321.
34. Hayden,M.S. et al. (2012) NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev., 26, 203-234.
35. Pineda-Molina,E. et al. (2001) Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. Biochemistry, 40, 14134-14142.
36. Pande,V. et al. (2009) Direct covalent modification as a strategy to inhibit nuclear factor-kappa B. Curr. Med. Chem., 16, 4261-4273.
37. Lipsky,J.J. et al. (2001) In vivo inhibition of aldehyde dehydrogenase by disulfiram. Chem. Biol. Interact., 130-132, 93-102.
38. Moon,K.H. et al. (2005) Inhibition of mitochondrial aldehyde dehydrogenase by nitric oxide-mediated S-nitrosylation. FEBS Lett., 579, 6115-6120.
39. Moreb,J.S. et al. (2008) ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol. Cancer, 7, 87.
40. Niture,S.K. et al. (2007) Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines. Carcinogenesis, 28, 378-389.
41. Krishna,I.V. et al. (2009) Cytotoxic studies of anti-neoplastic drugs on human lymphocytes-in vitro studies. Cancer Biomark., 5, 261-272.
42. Johansson,B. (1992) A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl., 369, 15-26.
43. Brar,S.S. et al. (2004) Disulfiram inhibits activating transcription factor/ cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol. Cancer Ther., 3, 1049-1060.
44. Bratasz,A. et al. (2006) Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc. Natl. Acad. Sci. U.S.A., 103, 3914-3919.
45. Fiorucci,S. et al. (2003) Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology, 124, 600-607.
46. Liu,L. et al. (2006) Targeted modulation of MGMT: clinical implications. Clin. Cancer Res., 12, 328-331.
47. Raza,H. (2011) Dual localization of glutathione S-transferase in the cytosol and mitochondria: implications in oxidative stress, toxicity and disease. FEBS J., 278, 4243-4251.
48. Marques,C. et al. (2006) The triage of damaged proteins: degradation by the ubiquitin-proteasome pathway or repair by molecular chaperones. FASEB J., 20, 741-743.
49. Ablain,J. et al. (2011) The drug-induced degradation of oncoproteins: an unexpected Achilles' heel of cancer cells? Cancer Discov., 1, 117-127.
50. Loo,T.W. et al. (2004) Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol. Pharm., 1, 426-433.
51. Wickström,M. et al. (2007) Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem. Pharmacol., 73, 25-33.
52. Shian,S.G. et al. (2003) Inhibition of invasion and angiogenesis by zincchelating agent disulfiram. Mol. Pharmacol., 64, 1076-1084.
53. Triscott,J. et al. (2012) Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget, 3, 1112-1123.
54. De Santo,C. et al. (2005) Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl. Acad. Sci. U.S.A., 102, 4185-4190.
55. ClinicalTrials.gov. Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver. http://clinicaltrials.gov/ct2/show/NCT00742911 (2 January 2013, date last accessed).